Novo Nordisk A/S (NVO) controlling shareholder Novo Holdings will receive a decision from European antitrust regulators on its proposed acquisition of Catalent (CTLT), by Dec. 6, Reuters reported on Monday, citing a European Commission filing.
The antitrust regulators can either allow the deal with or without modifications or launch a four-month investigation, Reuters reported.
Novo Holdings, Catalent, and the European Commission did not immediately reply to MT Newswires' requests for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 111.18, Change: -0.76, Percent Change: -0.67
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.